Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccine Recommendations and Guidelines of the ACIP


Section Navigation
			
			CDC Home








RSV ACIP Vaccine RecommendationsAdvisory Committee on Immunization Practices (ACIP)						Print
																Related Pages
										On This Page
			Current RecommendationsArchived
Published in Morbidity and Mortality Weekly Report (*MMWR*)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
CURRENT RSV Vaccine Recommendations
*MMWR*; October 13, 2023 / 72(41);1115–1122Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023Print version [8 pages]
See also:
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer Maternal RSV Vaccine | CDC
ACIP Evidence to Recommendations for Use of Pfizer RSVpreF in Pregnant People | CDC
*MMWR*; August 25, 2023 / 72(34);920–925Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among **Infants and Young Children**: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023Print version [6 pages]
See also:
GRADE: Nirsevimab, Season 1 | CDC
ACIP Evidence to Recommendations for Use of Nirsevimab in Infants born during the RSV season or entering their first RSV season | CDC
GRADE: Nirsevimab, Season 2 | CDC
ACIP Evidence to Recommendations for Use of Nirsevimab in Children 8–19 months of age with increased risk of severe disease entering their second RSV season | CDC
*MMWR*; July 21, 2023;72(29);793–801Use of Respiratory Syncytial Virus Vaccines in **Older Adults**: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023Print version [9 pages]
See also:
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): GSK RSVPreF3 Vaccine (AREXVY) | CDC
ACIP Evidence to Recommendations for Use of GSK Adjuvanted RSVPreF3 Vaccine (AREXVY) in Adults Ages 60 and Older | CDC
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer RSVpreF Vaccine (ABRYSVO) | CDC
ACIP Evidence to Recommendations for Use of Pfizer Bivalent RSVpreF Vaccine (ABRSYVO) in Older Adults | CDCARCHIVED RSV Immunization Publications
For your convenience, these archived publications can be used for historical and research purposes.
No archived articles at this time.**Top of Page
							
					
							Last Reviewed:  December 12, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Recs Home
Vaccine-Specific Recommendationsplus icon
Anthrax
Cholera
COVID-19
Dengue
DTaP/IPV/Hib/HepB
DTaP/Tdap/Td
Ebola
Hepatitis A
Hepatitis B
Hib
HPV
Influenza
Japanese Encephalitis
MMR
MMRV
Meningococcal
Pneumococcal
Polio
Rabies
Rotavirus
RSV
Smallpox
TBE
Typhoid
Varicella
Yellow Fever
Zoster (Shingles)
Recs Listed by Date
Comprehensive Recommendations and Guidelinesplus icon
General Best Practice Guidelinesplus icon
Introduction
History
Timing and Spacing of Immunobiologics
Contraindications and Precautions
Preventing and Managing Adverse Reactions
Vaccine Administration
Storage and Handling of Immunobiologics
Altered Immunocompetence
Special Situations
Vaccinations Records
Vaccination Programs
Vaccine Information Sources
Appendix 1: Glossary
Appendix 2: Membership
Archived ACIP Recs
Vaccine Recommendations for Emergency Situations To receive email updates about this page, enter your email address: Email Address			What's this?				Submit
 Vaccines & ImmunizationsVFC ResolutionsACIP Web SiteCDC's International Travelers Yellow BookClinical Travel Notices, Updates, and Vaccine Shortages


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue